• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Bonesupport Holding (OM:BONEX) Reports Stronger Profitability, Is The Upside Already Priced In?

    Simply Wall St·07/23/2026 05:28:17
    Listen to the news

    Bonesupport Holding (OM:BONEX) reported second quarter 2026 sales of SEK 355.72 million and net income of SEK 81.88 million, with higher earnings per share compared with the same period a year earlier.

    See our latest analysis for Bonesupport Holding.

    The latest results arrive after a mixed year for Bonesupport Holding, with the share price up 17.19% year to date but the 1 year total shareholder return down 33.95%. However, the 5 year total shareholder return of 160.42% points to stronger longer term momentum.

    If this earnings update has you thinking about where growth could come from next, it may be worth scanning other healthcare focused opportunities through our screener of 129 healthcare AI stocks

    Bonesupport Holding has just posted another set of strong numbers while the share price is still well below its 1 year high. Investors may be asking whether most of the potential upside is still ahead or if the stock has already done the hard work.

    Most Popular Narrative: 44.2% Undervalued

    The most followed narrative values Bonesupport Holding at SEK 373.83 per share compared with the last close of SEK 208.60, implying a wide gap that this framework seeks to explain through growth and margin assumptions rather than short term price moves.

    The launch momentum for CERAMENT G in the U.S. is accelerating, with a trend of high repeat usage and expansion into additional indications among existing customers, which is expected to positively impact future revenue growth. The submission of the CERAMENT V application to the FDA and potential NTAP reimbursement provide future catalysts for revenue growth and improved margins once approved and implemented.

    Read the complete narrative.

    Want to understand why this framework points to a significantly higher fair value for Bonesupport Holding? The story leans heavily on rapid top line expansion, rising profitability and a future earnings multiple that steps down from today yet still supports that higher valuation. Curious which specific growth and margin paths underpin that figure and how long they are assumed to last? The full narrative lays out the exact trajectory behind SEK 373.83.

    Result: Fair Value of SEK 373.83 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the Bonesupport Holding story could look very different if currency swings keep pressuring reported earnings, or if reimbursement support around CERAMENT products proves less durable than expected.

    Find out about the key risks to this Bonesupport Holding narrative.

    Another View on Bonesupport Holding’s Valuation

    The earlier fair value of SEK 373.83 for Bonesupport Holding comes from a narrative built around future earnings and margins. Looking at the current P/E of 64.2x against a fair ratio of 51.5x suggests the stock trades on richer terms, which could mean less room for error if growth or profitability undershoots.

    Compared with peers, the picture is mixed. Bonesupport Holding trades below a peer average P/E of 88.1x, yet well above the broader European biotechs average of 16.3x. Investors are therefore paying a clear premium to the sector even if it is cheaper than a selected peer group. The fair ratio of 51.5x is a level the market could move towards over time, which would imply a lower valuation multiple unless earnings rise enough to fill the gap. The real question is which reference point you trust most when judging risk and opportunity here.

    See what the numbers say about this price — find out in our valuation breakdown.

    OM:BONEX P/E Ratio as at Jul 2026
    OM:BONEX P/E Ratio as at Jul 2026

    Next Steps

    If this mix of signals around Bonesupport Holding leaves you with more questions than answers, it is worth reviewing the underlying data yourself and acting while it is fresh in mind. To see what investors are optimistic about and to weigh those potential upsides against the risks, take a closer look at the 4 key rewards.

    Looking for more investment ideas beyond Bonesupport Holding?

    Before you move on, this is a good moment to broaden your watchlist with other opportunities that match the way you like to invest.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.